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Simple Summary: In about 15–18% of breast cancers the HER2 gene is amplified, which allows an
anti-HER2 treatment. However, about 50% of HER2-positive patients experience de novo or acquired
resistance to the antibody-based therapy with trastuzumab. Therefore, the identification of predictive
markers for therapy success and novel combination strategies is needed. Here we explored the
impact of CX3CL1 on trastuzumab treatment efficiency and immunological mechanism involved in a
humanized tumor mouse model. Trastuzumab treatment showed pronounced efficiency in CX3CL1
overexpressing cancer cells compared to low expressing cells preventing lung metastasis, while the
administration of CX3CL1 shedding inhibition did not cause an enhanced treatment effect. Moreover,
the application of shedding inhibitors to CX3CL1 overexpression tumors resulted in a slightly
enhanced tumor growth. Therefore, the presence of CX3CL1 might predict a pronounced response to
trastuzumab therapy in patients and should be investigated in a large cohort of HER2+ patients.
Abstract: CX3CL1 is a multifunctional chemokine that is involved in numerous biological processes,
such as immune cell attraction and enhanced tumor immune cell interaction, but also in enhancing
tumor cell proliferation and metastasis. The multifarious activity is partially determined by two
CX3CL1 isoforms, a membrane-bound and a soluble version generated by proteolytic cleavage
through proteases. Here, we investigated the impact of CX3CL1 overexpression in MDA-MB-
453 and SK-BR-3 breast cancer cells. Moreover, we evaluated the therapeutic capacity of Matrix-
Metalloproteinases-inhibitors TMI-1 and GI254023X in combination with the anti-HER2 antibody
trastuzumab in vitro and in vivo. TMI-1 and GI254023X caused a reduced shedding of CX3CL1 and
of HER2 in vitro but without effects on tumor cell proliferation or viability. In addition, trastuzumab
treatment did not retard MDA-MB-453 cell expansion in vitro unless CX3CL1 was overexpressed
upon transfection (MDA-MB-453CX3CL1). In humanized tumor mice, which show a coexistence of
human tumor and human immune system, CX3CL1 overexpression resulted in a slightly enhanced
tumor growth. However, trastuzumab treatment attenuated tumor growth of both MDA-MB-
453CX3CL1 and empty vector transfected MDA-MB-453 transplanted mice but showed enhanced
efficiency especially in preventing lung metastases in CX3CL1 overexpressing cancer cells. However,
TMI-1 did not further enhance the trastuzumab treatment efficacy.
Keywords: CX3CL1; humanized tumor mice (HTM); trastuzumab; HER2; breast cancer; ADAM10;
ADAM17
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1. Introduction
Breast cancer (BC) is the most frequent malignant disease in women in the Western
world [1]. About 15–18% of the breast cancers belong to the HER2-positive (HER2+)
subtype that intrinsically exhibits a poor prognosis. However, therapy with the monoclonal,
humanized anti-HER2 antibody trastuzumab and other anti-HER2 therapeutic agents
considerably improved outcome of HER2+ BC in the past two decades, although about 50%
of patients still experience de novo or acquired resistance [2]. Thus, refining and enhancing
the anti-HER2 targeting, e.g., by a combined target-specific approach, is expected to
improve the clinical outcome in trastuzumab-treated patients.
Regardless of an anti-HER2 treatment, tumor immune cell infiltration (TIL) is asso-
ciated with improved outcome of the patients in particular in HER2+, but also in triple-
negative BC [3–5]. An antibody therapy such as trastuzumab impairs tumor cell growth
by direct cellular mechanisms, but also triggers NK cells by a mechanism known as
antibody-dependent cellular cytotoxicity (ADCC [6,7]). Therefore, the attraction of human
immune cells into the tumor microenvironment seems to be essential for a pronounced
therapeutic success.
CX3CL1 is a multifunctional chemokine, which is involved in a variety of tumor-
relevant processes, such as immune cell attraction and enhanced tumor–immune cell
interaction on the one hand, and in enhancing tumor cell proliferation, invasion, angio-
genesis and increased metastasis on the other hand [8]. CX3CL1 exists in two different
variants, the membrane-located form and the proteolytically cleaved and soluble domain.
CX3CL1 exhibits multiple cleavage sites leading to coexisting, differentially shed prod-
ucts [9]. The soluble CX3CL1, also called Fractalkine, has the capacity to attract different
immune effector cells (e.g., T and NK cells) into the tumor environment [10–12]. However,
it might also guide the CX3CR1-positive tumor cells out of the primary tumor towards
pre-metastatic niches, for instance towards the bone marrow (bm) [13]. The overexpression
of the corresponding receptor CX3CR1 has been associated with a higher tendency of
BC cells to spread to the skeleton [14] or to the brain [15]. Soluble CX3CL1 might also
bind to CX3CR1 expressing tumor cells and trigger tumor cell proliferation. This has
been first described in human smooth muscle cells mediated via the transactivation of
the epidermal growth factor receptor (EGFR; HER1)-dependent signaling by CX3CL1 [16].
Later on, Tardàguila and colleagues confirmed this CX3CL1 transactivation of the EGFR
pathway for BC using a HER2/neu transgenic mouse model [17]. In contrast to the sol-
uble variant, the membrane located CX3CL1 with its physiological function as adhesion
molecule [18] promotes stronger adhesion of leucocytes to CX3CR1-positive cells, and
therefore, might enhance T cell killing or NK cell mediated ADCC on trastuzumab coated
BC tumor cells [19].
The proteolytic cleavage (i.e., the extracellular shedding) of the membrane-bound
CX3CL1 to the soluble form is mainly mediated by metalloproteases ADAM10 (A Dis-
integrin and metalloproteinase domain-containing protein) [20,21] and ADAM17, also
known as tumor necrosis factor-α (TNFα)-converting enzyme (TACE) [19,21]. Different
inhibitors for ADAMs are available and a number of them are being currently subjected to
clinical trials. The inhibitor TMI-1 blocks ADAM17, ADAM10 and other MMPs and has
been shown to be effective on triple negative and HER2-overexpressing breast cancer cells.
GI254023X preferentially impairs ADAM10 activity [21], but to a lesser extend also inhibits
other MMPs as well as ADAM17.
The numerous activities of soluble and membrane-bound CX3CL1 might explain
ostensibly inconsistent reports on the impact of this chemokine on the course and outcome
of BC disease. For example, while Park et al. found a correlation between high CX3CL1 ex-
pression with a good prognosis and increased immune cell infiltration [22], others reported
a poor outcome of BC patients that was associated with CX3CL1-positive tumor cells [23].
Here, we evaluated the anti-tumor activity of a combined trastuzumab and TMI-
1/GI254023X treatment in the context of CX3CL1 expression. We tested the effects of
both ADAM inhibitors in vitro (MDA-MB-453 and SK-BR-3) and further applied TMI-1 in
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combination with trastuzumab in CX3CL1-expressing (MDA-MB-453CX3CL1) and control
(MDA-MB-453empty)-based HTM. HTM enable the assessment of treatment strategies under
human-like conditions, since they come with a coexisting human immune system and
human tumor growth as a result of the transplantation of human hematopoietic stems cells
and human BC cells into immunodeficient NSG mice [24–27].
2. Materials and Methods
2.1. BC Cell Lines and Treatments
MDA-MB-453 and SK-BR-3 used in this study were obtained from the American
Type Culture Collection (ATCC, LGC Standards, Wesel, Germany) and authentication was
confirmed in November 2017 and June 2018 from the German DSMZ Leibniz Institute by a
nanoplex PCR-based STR profiling. Cells were transfected as previously described [28].
Briefly, stable transfection was performed by using three µg of vector DNA (pCMV 6
mCX3CL1, pCMV 6 hCX3CL1, pCMV-6-Entry, Origene) and 6 µL of Lipofectin (Thermo
Fisher Scientific, Darmstadt, Germany). Transfected cells were selected with Neomycin
(Thermo Fisher Scientific, Darmstadt, Germany) for 14 days and positive clones used
for in vitro and in vivo testing after CX3CL1 measurement in an ELISA system (Human
CX3CL1/Fractalkine DuoSet ELISA, R&D Systems, Wiesbaden, Germany) according to
the manufacturer’s protocol. Cells were incubated and expanded in Dulbecco’s mod-
ified Eagle’s medium (DMEM), supplemented with 10% fetal calf serum (FCS) (both
PAA Laboratories, Pasching, Austria) and 0.5 mg/mL G418 (Geneticin Sulphate, Thermo
Fisher Scientific) under standard cell culture conditions. Cells were treated in vitro with
trastuzumab (5 µg/mL), ADAM Inhibitor TMI-1 (10 µM; PZ0336, Sigma-Aldrich, Darm-
stadt, Germany), and GI254023X (5 µM; SML0789; Sigma-Aldrich, Germany) for 48 h.
Untreated cells served as control samples. Supernatant from cell culture and serum from
MDA-MB-453 transplanted Humanized Tumor Mice (HTM) were tested for CX3CL1 (Hu-
man CX3CL1/Fractalkine DuoSet ELISA, R&D Systems, Germany) and soluble HER2
(Human ErbB2/Her2 ELISA, R&D Systems, Germany) according to the manufacturer’s
protocol. For the anti-HER2–trastuzumab competition assay, cells were stained for 60
min on ice with increasing trastuzumab concentrations (0–10 µg/mL), washed and after-
ward incubated for 20 min with the anti-HER2 FITC antibody (clone 24D2, BioLegend,
San Diego, CA, USA).
2.2. Western Blotting
Tumor cells were directly lysed in the cell culture flasks with cell-lysis buffer (Cell
Signaling, Danvers, MA, USA). The concentration of total protein was determined using
the BCA Protein Assay Kit (Pierce, Thermo Fisher Scientific, Rockord, IL, USA). Twenty
µg of protein samples were separated by a 10% SDS-PAGE and blotted onto a 0.2 µm
PVDF membrane by semi-dry wet blotting. Afterwards, the membrane was blocked in
5% BSA powder in TBS-T for one hour at room temperature. Incubation with the primary
antibody anti-ADAM 10 (1:1000; Cell Signaling, Danvers, MA, USA) and anti-β-actin
(1:5000; Sigma-Aldrich, Taufkirchen, Germany) was performed in TBS-T (supplemented
with in 2.5% BSA) overnight (4 ◦C). Secondary horseradish peroxidase (HRP)-conjugated
goat-anti rabbit IgG antibody (1:2000; Cell Signaling, Danvers, MA, USA) was incubated
for one hour at room temperature. Detection was performed using SuperSignal™ West
Pico PLUS Chemiluminescent Substrate (Thermo Fisher Scientific, Darmstadt, Germany)
and analyzed with the ImageQuant LAS 4000 mini (GE Healthcare, Buckinghamshire, UK).
2.3. Mice
NOD.Cg-Prkdcscid Il2rγtm1Wjl/SzJ (NSG) mice were obtained from Jackson Laborato-
ries and bred and kept in a specialized pathogen-free facility at the University of Regens-
burg. Humanized tumor mice were generated as previously described [24–26]. Briefly,
newborn mice were irradiated (1 Gy) and, 3 h later, transplanted with ~1–2 × 105 human
CD34+ cells isolated from umbilical cord blood (CB) using immunomagnetic beads (Mil-
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tenyi Biotech, Bergisch Gladbach, Germany). At the age of 8 weeks, humanized mice were
bled and the human reconstitution status (% CD45, CD3, CD19, CD33) were analyzed.
Humanized mice with >15% CD45/live cells were transplanted orthotopically with 50,000
(pilot study) and 1 × 106 MDA-MB-453CX3CL1 or MDA-MB-453empty in medium without
substitutions. Importantly, mice transplanted with the same CB sample were split into
different treatment and control groups. Treatment started when the tumor measured 5
mm in diameter with trastuzumab (5 mg/kg/week i.p.) or ADAM Inhibitor TMI-1 (100
mg/kg twice a week i.p.) for three weeks and analyzed 7 days after the last treatment
(Supplementary Figure S1).
2.4. Ethic Statements
The local veterinary authorities of the district government of Lower Franconia and
Upper Palatinate (Bavarian region) approved all animal work (permission no. 55-2-2532-2-
381). Cord blood samples were taken based on the approval given by the Ethics Committee
of the University of Regensburg (permission no. 16-101-0179). All patients included in the
study provided written informed consent.
2.5. Immunohistochemistry
Tissue specimens (tumor, spleen, liver, brain and lung) were prepared as previously
described [24–26]. Briefly, samples were fixed with 4% formalin and embedded in paraffin.
Four µm slides were prepared, deparaffinized and stained with anti-HER2 rabbit poly-
clonal A0485, anti-CK18 (clone DC 10), anti-CD20 (Clone L26) and anti-CD68 (Clone KP1)
from Dako GmbH (Jena, Germany) and anti-CD4 (clone SP35) and anti-CD8 (clone SP57)
from Ventana (Tucson, AZ, USA), Staining was performed automatically on a Ventana
Nexes autostainer (Ventana, Tucson, AZ, USA) by using the streptavidin-biotin-peroxidase
complex method and 3,3′-diaminobenzidine. Histological specimens were imaged with an
AxioImager Z1 microscope (Zeiss, Oberkochen, Germany).
2.6. Flow Cytometry Analysis
Flow cytometry was performed on a FACSCanto II flow cytometer (BD Biosciences,
San Jose, CA, USA) equipped with a blue (488 nm), violet (405 nm) and red (633 nm) laser
and the data were analyzed with FACSDiva Software v7.0 (BD Biosciences,San Jose, CA,
USA ). Unspecific binding was blocked by incubating the cells in 1% mouse serum for 10
min and appropriate mouse immunoglobulin antibodies were used as isotype controls for
all staining. Organs (spleen, tumor and lung) were dissociated by passing the cells through
40 µm cell strainer (BD Bioscience). Bone marrow (BM) cells were collected from the femur
by clipping the ends and flushing the bone cavity with 10 mL PBS using a syringe with a
27 G needle (BD Bioscience).
(a) Tumor cell phenotyping: Samples were stained using the following antibodies: anti-
HER2-FITC (clone 24D2, BioLegend), anti-CD47-PE (clone B6H12, BD Biosciences),
anti-CD44 Pe-Cy7 (clone G44-26, BD Biosciences), anti-c-MET APC (clone # 95106,
R&D Systems), anti-CD24 APC Vio770 (clone 32D12, Miltenyi Biotec, Bergisch Glad-
bach, Germany) anti-CD45 BV510 (clone H130, BioLegend, San Diego, CA, USA) and
anti-EPCAM BV421 (clone 9C4, BioLegend).
(b) Human immune cell reconstitution in spleen and tumor were analyzed with anti-
CD3-FITC (clone UCHT1), anti-CD19-PE (clone HIB19) and anti-CD45-APC (clone
HI30) from BD Bioscience and anti-CD33-PerCPCy5.5 (clone WM53) from BioLegend.
(c) T cell phenotyping was analyzed by anti-CD3-FITC (clone UCHT1, BD Bioscience),
anti-CD127-PE (clone A019D5, BioLegend), anti-CD27-PeCy7 (clone O323, eBioscience
(Thermo Fisher Scientific), Darmstadt, Germany), anti-PD-1-AF647 (clone EH12.2H7,
BioLegend), anti-CD4-APC-H7 (clone SK3, BD Bioscience), anti-CD8a-BV510 (clone
RPA-T8, BioLegend) and anti-CD45RA-BV421 (clone HI100, BioLegend)
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(d) NK cells were characterized by anti-NKp46-APC (clone 9-E2, BD Bioscience), anti-
CD16-PE (clone 3G8, BioLegend) and anti-CD56-Horizon™V450 (clone B159, BD
Bioscience).
(e) CX3CR3 expression on immune cells and tumor cells were analyzed by anti-HER2-
FITC (clone 24D2, BioLegend), anti-CD8-PE (clone HIT8a, BD Bioscience), anti-CD45-
APC (clone HI30, BD Bioscience), anti-CXCR3-BV421 (clone 2A9-1, BioLegend), anti-
CD4-APC-H7 (clone SK3, BD Bioscience), anti-CD19-BV510 (clone HIB19, BioLegend)
and anti-NKp46-APC (clone 9-E2, BD Bioscience). CX3CR1 expression on tumor cells
were performed by anti-CXCR3-BV421 (clone 2A9-1, BioLegend).
(f) Proliferation assessment: Cells were harvested by trypsinization and washed twice
with PBS, followed by fixation and permeabilization with cooled MeOH (70%) overnight.
Afterward the cells were washed and incubated for 20 min in the presence of RNase
(Roche Molecular Systems) at 37 ◦C and finally stained with 1 µg/mL DAPI prior to
analysis. Cell doublets, aggregates and ¬debris were excluded by pulse processing
and DNA histograms of the gated population were plotted on a linear scale. Cell
cycle fractions (% of cells in G0/G1-, S- and G2/M-phase) were analyzed using the
ModFit LT 3.2 software (Verity Software House, Topsham, ME, USA).
(g) Annexin V-FITC/DAPI Assay: Cells were cultured for 72 h in 10% FCS/DMEM
and treated for 48 h with trastuzumab, ADAM Inhibitor TMI-1 and GI254023X.
Untreated cells served as negative control. Cells were harvested by trypsinization
without discarding the supernatant and stained using the TACS Annexin-V-FITC
Apoptosis Detection Kit (ImmunoTools, Friesoythe, Germany) according to the manu-
facturer’s instructions.
2.7. Statistical Analyses
All results are shown as mean ± SEM. All reported p-values were two-sided. p-values
less than 0.05 were considered significant. For groupwise comparison, a one-way or
two-way analysis of variance (ANOVA) with Dunnett’s post-hoc test or Tukey’s multiple
comparisons were applied and the tests are indicated in each figure and table legend.
All statistical analyses were performed using GraphPad Prism (Ver. 6, GraphPad Software,
La Jolla, CA, USA).
2.8. List of Abbreviations
BC: breast cancer, BM: bone marrow, CB: cord blood, CTL: cytotoxic T lymphocytes,
HER2: human epidermal growth factor receptor 2, HSC: hematopoietic stem cells, HTM:
humanized tumor mice, mAbs: monoclonal antibodies, NK: natural killer.
3. Results
3.1. TMI-1 and GI254023X Inhibit CX3CL1 and HER2 Shedding In Vitro without Affecting
Tumor Cell Proliferation
MDA-MB-453 belong to the HER2+ subentity with a moderate HER2 gene amplifica-
tion (HER2/CEN17 ratio of 2.15) and HER2 overexpression [29]. These cells only express
very low levels of CX3CL1, which cannot be further elevated by inflammatory cytokines
such as TNF-α or IFN-γ [28]. For this reasons, MDA-MB-453 was chosen for the transfec-
tion experiments to identify the impact of CX3CL1 expression on tumor growth, metastases
formation and treatment efficiency of trastuzumab and ADAM inhibitors. Transfection
efficiency was determined by ELISA directly upon transfection and before each in vitro
and in vivo experiment (MDA-MB-453CX3CL1: 97 ng/mL ± 20.95 SEM, n = 6; MDA-MB-
453empty: 0.58 ng/mL ± 0.11 SEM, n = 6; p = 0.0010).
Proteolytic shedding of the membrane bound CX3CL1 is mainly mediated by met-
alloproteases ADAM10, which is expressed in SK-BR-3 and MDA-MB-453 (Figure 1A),
showing the premature ADAM10 with 90 kDa and to a lower extend the mature form of
ADAM10 with 60–70 kDa [30]. TMI-1 treatment resulted in significantly reduced CX3CL1
shedding from CX3CL1 transfected MDA-MB-453, whereas no reduction (and nearly no
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CX3CL1 concentration) could be observed in MDA-MB-453empty cells upon TMI-1 treat-
ment (Figure 1B). However, both TMI-1 as well as trastuzumab treatment impaired HER2
shedding in MDA-MB-453empty and in MDA-MB-453CX3CL1 cells (Figure 1C). Similar re-
sults were obtained in SK-BR-3, but due to the overall lower CX3CL1 expression upon
transfection (SK-BR-3CX3CL1: 14.18 ng/mL ± 7.3 SEM, n = 3; SK-BR-3empty: 1.89 ng/mL
± 0.79 SEM, n = 3; p = 0.0446), there was no significant difference in CX3CL1 in the su-
pernatant upon TMI-1 treatment (Supplementary Figure S2A), but a similar tendency as
shown for MDA-MB-453 cells.
Figure 1. CX3CL1 and HER2 shedding and expression in trastuzumab and TMI-1 treated MDA-MB-453 tumor cells.
MDA-MB-453 and SK-BR-3 cells were stably transfected with human Cx3CL1 (Cx3CL1+) or vector control (empty). (A) SK-
BR-3/MDA-MB-453CX3CL1 and SK-BR-3/MDA-MB-453empty were stained for ADAM 10 expression using western blot
technology. MDA-MB-453CX3CL1 and MDA-MB-453empty were cultured with a total concentration of 5 µg/mL trastuzumab
(Trast) and 10 µM TMI-1 for 48 h and supernatants were analyzed for CX3CL1 (B) or HER2 extracellular domain (HER2
ECD) (C) in comparison to DMSO treated control cells by ELISA. (D) HER2 expression intensity of the treated and
untreated MDA-MB-453 cells was analyzed by flow cytometry and the stain index (MFI = mean fluorescence intensity;
stain index = (MFIHer2 −MFIIsotype)/(2 (×) SDIsotype)) was calculated. (E) MFI and the stain index of the anti-HER2 staining
after 60 min of trastuzumab pre-incubation (with increasing concentration: 0–10 µg/mL) on ice are displayed. All
experiments were performed in triplicate. Data are shown as mean ± SEM and Tukey’s multiple comparisons test was
applied and significances are indicated (**p < 0.01; *** p < 0.001; **** p < 0.0001).
Interestingly, TMI-1 treatment did significantly reduce HER2 shedding of MDA-MB-
453 (HER2 ECD detection in ELISA; Figure 1C) and SK-BR-3 (Supplementary Figure S2B),
but the total HER2 expression on the cell surface using flow cytometry in both cell lines was
not affected (Figure 1D and S2C). By contrast, the application of trastuzumab attenuated
the HER2 shedding but also significantly reduced the cell surface HER2 expression (Figure
1D and S2C). Surprisingly, SK-BR-3empty cells showed a significant higher concentration
of soluble HER2 ECD (Supplementary Figure S2B) and increased HER2 expression (Sup-
plementary Figure S2C) compared to SK-BR-3CX3CL1. Titration of the anti-HER2 FACS
antibody on ice using MDA-MB-453 tumor cells against increasing trastuzumab concentra-
tion (0–10 µg/mL) did not impede HER2 staining (Figure 1E), suggesting that there was
no steric hindrance of trastuzumab and the anti-HER2 detection antibody but possibly
enhanced internalization of HER2 by trastuzumab [31].
Analyses of cell viability revealed no apoptotic effect in any SK-BR-3 or MDA-MB-453
(Supplementary Figure S3A,B) tumor cells caused by TMI-1 or trastuzumab treatment.
In addition, there were no significant changes in cell cycle progression of MDA-MB-
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453 cells (Supplementary Figure S3C,D), except for a significant reduction of S-phase in
trastuzumab-treated MDA-MB-453CX3CL1 cells, which indicates a higher sensitivity of these
cells to the antibody treatment (Supplementary Figure S3C). As expected, in SK-BR-3CX3CL1
(Supplementary Figure S2D) and SK-BR-3empty (Supplementary Figure S2E), trastuzumab
significantly reduced S-phase proportion, and thereby, increased G1-phase fraction without
an (additional) effect by TMI-1 treatment.
Similar results were obtained by using the inhibitor GI254023X, which is supposed to
mainly block ADAM10: a significant reduction of CX3CL1 (Supplementary Figure S4A,
data shown for MDA-MB-453CX3CL1) and HER2 (Supplementary Figure S4B) shedding was
revealed. The exposition to GI254023X also had no effect on cell number, cellular apoptosis
(Supplementary Figure S4C,D) or cell cycle progression (Supplementary Figure S4E,F) of
MDA-MB-453empty and in MDA-MB-453CX3CL1 cells, respectively.
3.2. Trastuzumab Efficiently Blocked Tumor Growth with Enhanced Efficiency in CX3CL1
Overexpressing MDA-MB-453-Based HTM
Next, we investigated the effect of CX3CL1 expression and the impact of ADAM in-
hibitors using the humanized tumor mouse model (HTM), which allowed the investigation
of the impact of CX3CL1 on tumor growth, metastatic spread and human immune cell
modulation. The in vitro analysis revealed a rather low CX3CL1 expression in SK-BR-3
cells upon CX3CL1 transfection. Therefore, MDA-MB-453 cells were used to generate HTM
for the in vivo study.
Histological staining of the primary tumors in HTM revealed variable HER2 expres-
sion levels in different tumor areas, but continuously high CK18 levels (Figure 2A), which
proves human tumor origin (i.e., MDA-MB-453 cells). Immune cell infiltration was also de-
tected in specific areas of the tumor tissue, showing infiltration of CD4+ T cells and CD68+
cells but rarely CD8+ T or B cells. B cells (CD20) were mostly found in the surrounding
stroma (Figure 2A).
Figure 2. Treatment efficiency of trastuzumab and TMI-1 in MDA-MB-453-transplanted HTM. MDA-MB-453CX3CL1 and
MDA-MB-453empty were transplanted orthotopically in humanized NSG mice. Animals were randomized to receive
trastuzumab (Trast), TMI-1, Trast+TMI-1 or DMSO control. (A) Immunhistological staining of tumor tissue (exemplarily
shown for a one-time trastuzumab-treated HTM) for human HER2, cytokeratin 18, T helper (CD4), cytotoxic (CD8) T cells,
macrophages (CD68) and B cells (CD20 in the periphery of the tumor and in the connective tissue). Red arrows indicate
CD20+-stained cells. Tumor growth over time in MDA-MB-453CX3CL1. Scale bar represents 50 µm. (B) and MDA-MB-
453empty (C) in the different treatment groups is shown and summarized in (D). Tumor volume (E) and tumor weight (F) of
the treated HTM and the correlation (G) between both parameters were analyzed (Pearson’s correlation coefficient r = 0.9008).
(D–F) Data are shown for HTM, which achieved the end of the experiments (control n = 6; Trast n = 6, TMI-1 n = 5; TMI-1 +
Trast n = 5) as mean ± SEM. Dunnett’s multiple comparison test (D–F; * p < 0.05; ** p < 0.01; *** p < 0.001, **** p < 0.0001)
and Sidak’s multiple comparisons test (D, red bars; * p = 0.037) were applied and significances are indicated.
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Nearly three weeks post tumor cell transplantation, tumors were detectable (mean
days post transplant: 19.2 days ±1.8 SEM; n = 49 tumor) and monitoring of tumor growth
was started. To ensure high CX3CL1 expression in vivo until the end of the experiments,
CX3CL1 concentration in the tumors was analyzed in a pilot study. Constantly increased
levels of CX3CL1 were detected after an average of 90 days upon transplantation in
MDA-MB-453CX3CL1 (737.2 pg/µg ± 500 SEM; n = 5) versus MDA-MB-453empty vector
transfection (4.7 pg/µg CX3CL1 ± 1.4 SEM; n = 2) in HTM. Therefore, during the ~7-week
treatment study, a high concentration of CX3CL1 in the tumor of MDA-MB-453CX3CL1 HTM
was warranted.
Overall, there was an inhibition of tumor growth by trastuzumab treatment alone or in
combination with TMI-1 in MDA-MB-453CX3CL1 and MDA-MB-453empty HTM (Figure 2B,C).
The analyses of tumor development over time (Figure 2D) revealed a significantly re-
duced tumor growth in trastuzumab-treated MDA-MB-453empty (* p = 0.0201; Trast +
TMI-1: ** p = 0.0082) and an even more pronounced difference upon trastuzumab treat-
ment in MDA-MB-453CX3CL1 (**** p < 0.0001). Surprisingly, in MDA-MB-453CX3CL1, HTM
TMI-1 showed a slightly enhanced tumor growth over time in comparison to control
(Figure 2D; * p = 0.0475). There were no differences between MDA-MB-453CX3CL1 and
MDA-MB-453empty transplanted HTM detectable besides between TMI-1 treated mice
(Figure 2D, red bar; p = 0.037). The treatment efficiency of trastuzumab (but not of TMI-1)
is also reflected by the final tumor volume (Figure 2E) and the tumor weight (Figure 2F).
Detailed information of each HTM is listed in the Supplementary Materials (Supplementary
Table S1). As expected, there is a significant correlation between tumor weight and volume
(Figure 2G; Pearson’s r = 0.9008).
3.3. Increased CD44 Expression In Vivo on MDA-MB-453CX3CL1 and MDA-MB-453empty
Primary Tumor Cells
The characterization of tumor cell marker expression (exemplarily shown in Figure 3A)
on EPCAM+ MDA-MB-453 cells isolated from the solid tumors of HTM revealed HER2,
CD47, cMET, CD24 and CD44 expression. Tumor cells isolated from HTM (black histogram,
Figure 3B) showed similar expression profiles of cMET and CD24 and slightly different
HER2 and CD47 patterns (Figure 3B) compared to cell culture cells (grey histogram; Figure 3B).
There were no differences between MDA-MB-453CX3CL1 and MDA-MB-453empty cells or
between treatment groups detectable when these markers were analyzed. However, CD44
expression on tumor cells in vivo (primary tumor) was significantly increased compared
to cell culture cells (Figure 3C). More specifically, in vitro cells only exhibited a small
subfraction of CD44+ tumor cells (Figure 3B, dot plot). CD44 expression also showed
a variation between the treatment groups with the weakest expression in TMI-1-treated
MDA-MB-453CX3CL1 and MDA-MB-453empty HTM (Figure 3C, not significant).
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Figure 3. Tumor cell phenotyping and HER2 shedding detected in the serum of MDA-MB-453 HTM. Humanized NSG
mice were transplanted with 1 × 106 MDA-MB-453CX3CL1 and MDA-MB-453empty and tumor cells were analyzed by flow
cytometry. (A,B) Histogram of tumor cells stained with HER2, CD47, cMET, CD24 and CD44 are displayed (A: isotype
control = grey; tumor isolated from HTM = black; B: cell culture = grey; tumor isolated from HTM = black). Dot plot shows
the low percentage of CD44+ MDA-MB-453 tumor cells from the cell culture. (C) Percentage of CD44 expression on HER2+
tumor cells from cell culture compared with tumor cells isolated from the primary tumor of HTM are summarized. (D) Shed
serum HER2 extracellular domain (sHER2 ECD) was detectable in the serum of HTM. Data are shown as mean ± SEM
and significances were calculated using Tukey’s multiple comparisons test (*p < 0.05). (E) Graph outlines the correlation
between sHER2 ECD and tumor volume (Pearson’s correlation coefficient r = 0.4130).
Shed HER2 extracellular domain (sHER2 ECD) could also be detected in the serum of
HTM and revealed a significant reduction of sHER2 ECD in trastuzumab-treated (alone
or in combination with TMI-1) HTM (Figure 3D). The amount of sHER2 ECD showed a
moderate correlation to the corresponding tumor volume (Figure 3E; Pearson’s r = 0.4130;
p = 0.0043).
3.4. Trastuzumab Treatment Significantly Reduced Lung Metastases in MDA-MB-453CX3CL1- but
Not in MDA-MB-453empty-Based HTM
All MDA-MB-453 transplanted control mice developed lung metastases (Figure 4A;
Table 1), which could only be significantly reduced in trastuzumab-treated MDA-MB-
453CX3CL1 (p = 0.0047) but not in MDA-MB-453empty-transplanted mice (Table 1). However,
the combined trastuzumab/TMI-1 treatment significantly reduced lung metastases in both
MDA-MB-453CX3CL1- and MDA-MB-453empty-transplanted mice (Table 1; *B p = 0.0152; *C
p = 0.0333). Nevertheless, there was an individual and wide variation of tumor cell density
in the lung of the analyzed HTM (Figure 4B).
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Figure 4. Metastases formation in MDA-MB-453-transplanted humanized tumor mice (HTM). (A) Immunohistochemical
HER2 staining of a lung tissue exemplarily shown in a TMI-1-treated MDA-MB-453CX3CL1-transplanted HTM. Red arrows
indicate tumor cells in the lung tissue. Metastases formation in the lung of HTM were analyzed by flow cytometry
using an anti-HER2 antibody (B). (Ci–iii) Analysis of the bone marrow (bm) samples from the femurs revealed two
different tumor cell populations (EPCAM+HER2- and EPCAM-HER2+). CD44 expression on EPCAM-HER2+ (D) and
EPCAM+HER2-(E) were analyzed using a multicolor panel. Data are shown as mean ± SEM, and significances were
analyzed using Tukey’s multiple comparisons (* p < 0.05; ** p < 0.01; **** p < 0.0001).
Table 1. Detection of tumor cells in the lung of control versus treated HTM.
HER2+ Lung Metastases MDA-MB-453CX3CL1 (n/n) MDA-MB-453empty (n/n)
Control 6/6 6/6
TMI-1 3/5 4/5
Trast 1/7 *A 3/6
Trast and TMI-1 1/5 *B 1/4 *C
Single cells from the lung were analyzed by flow cytometry. The number of animals with detectable HER2+ tumor
cells of the total number of animals (n/n) is given. Statistical differences were calculated using the two-sided
Fisher’s exact test and significant differences between control and trastuzumab (Trast; *A p = 0.0047) or control
versus trastuzumab + TMI-1 (*B p = 0.0152; *C p = 0.0333) are indicated in the table.
Nearly all HTM showed HER2+ tumor cells in the bone marrow (bm), but neither
trastuzumab nor TMI-1 treatment was able to completely eliminate these HER2+ dissem-
inated tumor cells (DTCs) (Table 2; Figure 4C). Interestingly, an additional tumor cell
population developed in the bm niche (which was not detectable in the lung) expressed EP-
CAM but lost HER2 on the cell surface (Figure 4C-i). This EPCAM+HER2- DTC population
represented the majority of DTC in all HTM (~1% of bm cells (Figure 4C-iii) compared to
~0.5% HER2+ DTCs (Figure 4C-ii)). HER2+ DTCs displayed similar to the analyzed primary
tumor an increased CD44 expression compared to cell culture MDA-MB-453 (Figure 4D).
This finding was independent of the applied treatments, whereas the increased CD44 ex-
pression in EPCAM+HER2- DTCs exhibited higher variability in increased CD44 expression
between treatments (Figure 4E).
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Table 2. Detection of tumor cells in the bm of control versus treated HTM.




Trast and TMI-1 3/5 2/3
Single cells from the femur were analyzed by flow cytometry and HTM with detectable HER2+ tumor cells were
counted. The number of animals with detectable HER2+ tumor cells of the total number of animals (n/n) is
given. Statistical differences were calculated using the two-sided Fisher’s exact test and revealed no significant
differences.
3.5. MDA-MB-453CX3CL1-Transplanted HTM Developed Enlarged Spleens but Showed Similar
High Human Immune Cell Reconstitution as MDA-MB-453empty-Transplanted Mice
Spleens were significantly enlarged in MDA-MB-453CX3CL1-transplanted mice
(0.077 g ± 0.009 SEM; n = 16) compared to the spleen inspected in MDA-MB-453empty
HTM (0.049 g ± 0.005 SEM; n = 11¸ Figure 5A). Especially, four MDA-MB-453CX3CL1 HTM
generated with four different cord blood donors showed an increased weight of this organ
(one control, two trastuzumab and one trastuzumab + TMI-1 treated HTM; Figure 5A).
At the age of eight weeks post HSC transplantation (before the animals were assigned to the
experimental groups), mice were bled and the human reconstitution (% human CD45/live
cells) was assessed. According to these results, humanized mice from the different donors
were equally assigned to the respective groups (treatment and MDA-MB-453empty/CX3CL1).
Figure 5. Human immune cell distribution in the spleen and bone marrow of MDA-MB-453CX3CL1 and MDA-MB-453empty
HTM. (A) Spleen weight and representative spleen image of MDA-MB-453CX3CL1 and MDA-MB-453empty transplanted
HTM is displayed and significance was calculated using Student’s t-test (p = 0.0367). (B) The percentages of human CD45+
immune cells in the spleen and bone marrow were analyzed using flow cytometry and differences were calculated using
Student’s t-test. (C) Immune cell subsets in the spleen were stained with antibodies against CD4 (T helper cell), CD68
(macrophages), CD8 (cytotoxic T cell) and CD20 (B cell) antibody. Scale bar represents 50 µm.
At the end of the experiments, spleen and bm cells were isolated and analyzed for
human immune cell populations (gating strategy is shown in Supplementary Figure S5A,B).
Both MDA-MB-453CX3CL1- and MDA-MB-453empty-transplanted mice showed high human
reconstitution levels in the spleen (MDA-MB-453CX3CL1: 58.5 ± 3.4 SEM, n = 24; MDA-
MB-453empty: 65.2 ±4.6 SEM; n = 23) and the bm (MDA-MB-453CX3CL1: 56.7 ± 3.4 SEM,
n = 22; MDA-MB-453empty: 49.4 ± 5.3 SEM; n = 16) (Figure 5B). Immunohistological
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staining revealed a B cell (CD20) cluster formation in the spleen surrounded by CD68+
macrophages, which was accompanied by high numbers of CD4+ and lower number of
CD8+ T cells (Figure 5C). There was a significant correlation between human immune
cells in the blood (at the age of 8 weeks) and at the end of the experiment in the spleen
(Pearson’s r = 0.5681; p < 0.0001; Supplementary Figure S5C). Therefore, the assignment of
the humanized mice into the different groups (MDA-MB-453empty, MDA-MB-453CX3CL1
and treatment groups) based on the blood reconstitution at 8 weeks is feasible because
it reflects the human immune cell reconstitution in the spleen, and therefore, the overall
human immune cell repopulation in HTM. Notably, there were no differences in the overall
human reconstitution or immune cell distribution between MDA-MB-453CX3CL1 and MDA-
MB-453empty in the spleen or BM (Supplementary Figure S5D,E). NK cells were analyzed
in more detail (CD16, CD56 and CD27 expression), but no change in the overall percentage
of NK cells (~1.3% of human cells) was found. In addition, no differentiation into the NK
cell subpopulation (CD56/CD16) was measurable (the majority of NK cells showed CD56
expression (~65% in all groups), but a lower percentage showed CD16 expression (~36% in
all groups).
3.6. Rejection of Tumor Was Associated with Increased CD4+ T Cell Fraction and Maturation in
HTM
A pretesting of cell engraftment in HTM using only 50,000 MDA-MB-453 tumor
cells for s.c. transplantation yielded tumor outgrowth, though not in all transplanted
mice. The immune cell analyses revealed a significant higher CD4 proportion in those
animals without detectable tumor growth (Supplementary Figure S6B). Furthermore, CD4+
(Supplementary Figure S6C) as well as CD8+ (Supplementary Figure S6D) T cells showed
an increased maturation stage (memory phenotype; gating strategy, Supplementary Figure
S6A) in tumor-free HTM, suggesting an effective T cell defense against low tumor cell
count transplantation.
However, using 1 × 106 tumor cells resulted in tumor engraftment in all transplanted
mice. There were no significant differences in CD4/CD8% on T cells (Figure 6A and S6B)
or maturation of CD4+ (Figure 6B and S6C) and CD8+ (Figure 6C and S6D) cells between
MDA-MB-453CX3CL1 or MDA-MB-453empty. As previously found in HTM [24,26], CD4+ T
cells were most often higher in number and showed advanced maturation compared to
CD8+ T cells. Accordingly, PD-1 expression (Figure 6D gating strategy), as a marker for
immune cell activation, was also higher in CD4 T cells (mean 35.3% CD4 ± 3.7 SEM; n =
38) compared to CD8 T cells (mean 12.67% CD8 ± 2.2 SEM; n = 39).
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Figure 6. Human T cell subpopulation in the spleen upon transplantation with 1 × 106 MDA-MB-453CX3CL1 and MDA-
MB-453empty cells into humanized mice. Humanized NSG mice were transplanted with 1 × 106 MDA-MB-453CX3CL1 and
MDA-MB-453empty and spleen cells were analyzed by flow cytometry. The proportion of CD4+ and CD8+ T cells (A) and
the different CD4+ (B) and CD8+ (C) subsets (naïve, memory (mem), memory effector, and terminally differentiated effector
memory (TEMRA)) are displayed (mean of each subset is shown as average %). (D) PD-1 expression on CD4+ and CD8+
(CD4−) were analyzed. Differences in dependency of MDA-MB-453CX3CL1/MDA-MB-453empty or treatment are displayed
for CD4 (E) and CD8 (F) T cells. The correlation between PD-1 expression and a memory phenotype of CD4+ (G) and CD8+
(H) T cells was calculated (Pearson’s correlation coefficient r = 0.8076 and r = 0.7150). (I) The percentage of human immune
cells (CD45+) infiltrating into the tumor tissue was analyzed (Student’s t-test p = 0.2352).
However, the CD4/CD8 proportion, the phenotypes and the PD-1 expression levels
were independent of CX3CL1 overexpression and the applied treatments (Figure 6E,F and
S6). Notably, there is a strong correlation between the maturation stage of T cells and PD-1
expression in CD4+ (Pearson’s r = 0.81; p < 0.0001; Figure 6G) and CD8+ (Pearson’s r = 0.72;
p < 0.0001; Figure 6H) T cells, which strongly indicates that PD-1 expression is associated
with an advanced maturation level in HTM.
Analyses of the tumor tissue revealed an overall low immune cell infiltration (range:
0–2.5%; Figure 6I) in MDA-MB-453 transplanted HTM with a majority of T cells (MDA-
MB-453CX3CL1 HTM: 66.4 ± 7.6 SEM; MDA-MB-453empty HTM: 64.2 ± 7.2; data not shown)
followed by CD33+ myeloid cells (MDA-MB-453CX3CL1 HTM: 18.1 ± 4.7 SEM; MDA-MB-
453empty HTM: 20.4 ± 5.8 SEM) and B cells (MDA-MB-453CX3CL1 HTM: 7.9 ± 4.7 SEM;
MDA-MB-453empty HTM: 8.5 ± 3.2, n = 15 for all groups). Again, these finding were
independent of CX3CL1 overexpression and treatment modalities.
3.7. CX3CR1 Expression on Tumor Cells Was Significantly Increased In Vivo
CX3CR1 expression on tumor cells in cell culture were low, with an average of 0.8%
CX3CR1+ tumor cells (±0.1 SEM; n = 6), which was independent of CX3CL1 expression
(Figure 7A). However, in vivo CX3CR1 expression was significantly increased in all HTM
but slightly affected by the different treatments (Figure 7B).
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Figure 7. CX3CR1 expression on tumor and immune cells in vitro and in vivo. (A) Density dot plots of MDA-MB-453
(CX3CL1 or empty vector transfected) from cell culture stained with anti-CX3CR1 antibody. (B) CX3CR1 expression on
MDA-MB-453CX3CL1 and MDA-MB-453empty tumor cells isolated from the primary tumor of HTM compared with the same
cells under cell culture conditions. (C) Histograms of CX3CR1 expression on B cells, CD4, CD8 and NK cells. Percentage of
CX3CR1 expression on the different immune cells isolated from the spleen (D) and tumor (E) of MDA-MB-453-transplanted
mice. Data are shown as mean ± SEM and Tukey’s multiple comparisons test was applied and significances are indicated
(*p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001).
CX3CR1 expression was also detectable on different human immune cell populations
in the HTM (exemplarily shown in Figure 7C) but independent of treatment or CX3CL1
overexpression (Figure 7D). The highest proportion of CX3CR1+ spleen cells were found
on NK cells followed by CD4 and CD8 T cells (Figure 7D). B cells isolated from the spleen
showed the lowest CX3CR1 content. Similar CX3CR1 profiles on the different immune
cells were found on the tumor infiltrating immune cells (Figure 7E).
4. Discussion
The importance of CX3CL1 in cancer biology is still being discussed and remains
controversial. This might in part be due to the existence of two isoforms, i.e., a “soluble”
and “membrane-bound” variant, and their different activities.
On the one hand, CX3CL1 seems to be associated with an enhanced immune cell
infiltration into the tumor tissue, which contributes to a better outcome of, e.g., colorec-
tal [32], gastric [33] and BC disease [22]. Moreover, membrane-bound CX3CL1 has been
described to activate NK cell cytotoxicity [34], possibly triggered by an enhanced binding
to the target cells [19]. However, in HTM, we did not detect CX3CL1-induced chemotactic
function, which would be reflected by an increased immune cell tumor infiltration in
CX3CL1 overexpressing MDA-MB-453 tumors, but we observed enlarged spleens in these
mice. The low amount of immune cell infiltration observed in MDA-MB-453-based HTM
seems to be due to the low immunogenicity of MDA-MB-453. Unlike MDA-MB-231-based
HTM, HTM in general show a much higher degree of immune cell infiltration (unpub-
lished data), and therefore, CX3CL1 expression might be more effective in these mice.
However, as MDA-MB-231 cells do not express HER2, they were not suitable to study
CX3CL1/trastuzumab synergies.
On the other hand, not only an anti-tumorigenic, but also a tumorigenic activity has
been attributed to CX3CL1. For example, an enhanced formation of metastases in BC,
especially to the bones, as a function of CX3CL1 has been reported [13–15]. However, this
cannot be confirmed by the HTM experiments as performed in this study. There was no
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significantly enhanced formation of lung metastases or DTC accumulation in the bone
marrow in MDA-MB-453CX3CL1 mice, even though the CX3CL1 receptor CX3CR1 was
strongly upregulated in MDA-MB-453 tumor cells. Due to the limitation in single cell
numbers that could be isolated from the lung and the bone marrow, CX3CR1 expression
on lung and bone marrow tumor cells was not analyzed. However, we assume that the
CXCR1 expression in vivo is generally increased, and therefore, appears to be expressed at
the same density as seen in primary tumor cells.
In the solid tumor, we observed slightly enhanced tumor growth in CX3CL1 overex-
pressing tumors. An increased tumor growth under the influence of CX3CL1 has also been
described for MDA-MB-453 and HT 29 transplanted SCID mice during the first period
of engraftment (publication under review). The tumorigenic effect of CX3CL1 might be
explained by the transactivation of EGFR downstream pathways that results in a stimu-
lation of cell proliferation [17]. Notably, MDA-MB-453 tumor cells in vitro do not come
with an EGFR gene amplification and do not express EGFR (analyzed by FISH and western
blotting; unpublished data). Nevertheless, in MDA-MB-453-based HTM tumors, we found
some degree of heterogeneity and EGFR positive tumor areas. Irrespective hereof, other
authors described an enhanced tumor growth due to the stimulation of angiogenesis by
CX3CL1 [35–38], which was not examined in HTM.
In this study, the predominant effect of CX3CL1 was the enhanced trastuzumab
efficiency in MDA-MB-453CX3CL1-transplanted HTM. In vitro, trastuzumab treatment does
not impair the viability of CX3CL1 overexpressing MDA-MB-453 or SK-BR-3 cells and does
not significantly attenuate cell proliferation. In contrast, tumor growth of all MDA-MB-453-
based HTM (MDA-MB-453empty and MDA-MB-453CX3CL1) was significantly reduced by
trastuzumab treatment. The therapeutic effect seems to be in part due to an immune cell
activation that results in an immunological tumor defense, e.g., mediated by ADCC [7].
However, CX3CL1-expressing MDA-MB-453 HTM treated with trastuzumab showed
a slightly enhanced inhibition of tumor growth indicated by an enhanced significance
between control and trastuzumab treated HTM (MDA-MB-453empty p = 0.0201versus
MDA-MB-453CX3CL1 p > 0.0001) and a significantly reduced formation of lung metastases.
This would confirm the assumption of CX3CL1 as a trigger for the activation of effector
cells and promotor for stronger adhesion of leucocytes to CX3CR1-positive tumor cells as
postulated before [19].
The CX3CR1 expression on different human immune cell subsets in HTM, predomi-
nantly on NK cells, supports this consideration. CX3CR1 expression was also found on
activated cytotoxic T cells [39]. Correspondingly, we found in HTM human T cells with an
upregulated PD-1 expression upon activation and maturation. These PD-1+/CD8+ infil-
trating T cell have been characterized as tumor-specific and cytotoxic T cells in the clinical
setting [40]. However, differences in T and NK cell maturation, or in PD-1 and CX3CR1
expression in spleen or tumor cells were not measurable between MDA-MB-453empty- and
MDA-MB-453CX3CL1-based HTM or between the treatment groups.
The application of the ADAM inhibitors TMI-1 as well as GI254023X blocked CX3CL1
shedding in vitro but without affecting the tumor cell viability or proliferation. TMI-1
mainly but not exclusively blocks ADAM17, a cell membrane located sheddase, which has
more than 70 different substrates, amongst them CX3CL1, but also HER2, CD44, CD16,
c-MET, MICA/B, EGFR, FASL and PD-L1 and growth factors such as TGF-α, amphireg-
ulin, epiregulin and HB-EGF, which are released upon cleavage [41–43]. ADAM17 has
been found overexpressed in various human cancers including BC [44] and has been as-
sociated with cancer progression, proliferation and migration [45], as well as with poor
prognosis [46]. Therefore, the inhibition of ADAM17 might affect multiple tumor-relevant
molecules and corresponding pathways. In the transgenic MMTV-ERBB2/neu mouse
model, 30 days of TMI-1 treatment has been described to reduce tumor growth [47], but
Tardáguila described a downregulation of CX3CL1 in the tumors of these mice compared to
the healthy tissue. Moreover, the CX3CL1 transfection increased tumor formation in a dose-
dependent manner [17]. Therefore, the role of TMI-1 in the context of CX3CL1 in this mouse
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model is difficult to determine. In MDA-MB-453CX3CL1–based HTM, TMI-1 treatment re-
sulted in a slightly increased tumor growth in comparison to MDA-MB-453empty-based
HTM, which suggests a pro-proliferative effect of membrane-bound CX3CL1 or the missing
anti-proliferative effect of the soluble form. In summary, this study provides evidence for
CX3CL1 contributing on the one hand to tumor growth and on the other hand to enhanced
response to trastuzumab treatment in MDA-MB-453-transplanted HTM. However, an addi-
tional effect of ADAM inhibition could not be observed. In general, HTM are generated
by using different cord blood donors in a combination of allogenic tumor cells, which
might cause individual immune cell responses. Using different therapy modalities (e.g.,
long term TMI-1 substitution, increased concentration and others) might improve ADAM
inhibitor efficacy but harbors the risks in term of side effects since ADAM enzymes are
known to be expressed not only on target cells but on a variety of cells. GI254023X blocks
mainly ADAM10 activity, which is responsible for the shedding of similar targets, includ-
ing CX3CL1, EGFR, CD44 and HER2, as has also been described for ADAM17. Mullooly
et al. described an impaired migration and invasion of MDA-MB-453 cells in vitro when
exposed to GI254023X, but they also did not observe any effect on cell proliferation or
survival [20]. In an in vivo orthotopic glioblastoma xenograft model, the application of
GI254023X exhibited pronounced growth reduction [48]. However, the authors applied the
inhibitor to block the cleavage and secretion of the synaptic adhesion molecule neuroligin-3
(NLGN3), and thereby, reduced its growth promoting function rather specific for glioma
cells. Therefore, ADAM inhibition might act differently on individual tumor types depend-
ing on the molecules involved in proliferation or other tumor-specific pathways regulated
by shedding.
A possible read-out parameter for treatment effectiveness in HER2+ BC in future HTM
studies could be the degree of soluble HER2 ECD in the serum, which was reduced in
trastuzumab-treated HTM and which correlated with a reduced tumor volume. The soluble
ECD in the serum of patients has been also proposed to represent a marker for therapy
response in humans [49]. The reduced serum ECD has also been described as a response
marker to another ADAM inhibitor (i.e., INCB7839) tested in a single arm open label
trial in combination with trastuzumab. Upon trastuzumab/INCB7839 administration,
patients with HER2+ BCs showed a reduced concentration of ECD in the blood serum,
and consequently, reduced constitutively active kinase p95-HER2, which was associated
with an increased clinical response rate [50]. However, INCB7839 single-treated patients
(without trastuzumab) were not included in this trial. The HTM experiments performed in
this study revealed a reduced ECD concentration in the serum associated with reduced
tumor size caused by trastuzumab treatment (with or without the application of TMI-1)
but not in mice treated exclusively with TMI-1.
5. Conclusions
Overall, this study provides evidence for CX3CL1 contributing on the one hand
to tumor growth and on the other hand to enhanced therapy response to trastuzumab
treatment in MDA-MB-453-transplanted HTM. However, the inhibition of ADAMs by
TMI-1 did not enhance the trastuzumab treatment success, neither in vitro nor in vivo,
possibly hampered by the multifaceted effects of ADAM inhibitors. Nevertheless, the
prognostic value of CX3CL1 expression in trastuzumab treated BC patients might be
worth investigating. Once confirmed by the evaluation on human tumor samples, new
approaches to enhance local CX3CL1 expression in combination with trastuzumab therapy
should be tested in relevant pre-clinical models.
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cell reconstitution in MDA-MB-453CX3CL1- and MDA-MB-453empty-transplanted HTM, Figure S6:
CD4+ and CD8+ T cell maturation in HTM transplanted with a reduced number of MDA-MB-
453CX3CL1- and MDA-MB-453empty cells, Table S1: Overview of tumor load and metastasized tumor
cells in the lung and bone marrow of individual MDA-MB-453CX3CL1- and MDA-MB-453empty-
transplanted HTM.
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8. Korbecki, J.; Simińska, D.; Kojder, K.; Grochans, S.; Gutowska, I.; Chlubek, D.; Baranowska-Bosiacka, I. Fractalkine/CX3CL1 in
Neoplastic Processes. Int. J. Mol. Sci. 2020, 21, 3723. [CrossRef]
Cancers 2021, 13, 2459 18 of 19
9. Haskell, C.A.; Cleary, M.D.; Charo, I.F. Unique role of the chemokine domain of fractalkine in cell capture. Kinetics of re-ceptor
dissociation correlate with cell adhesion. J. Biol. Chem. 2000, 275, 34183–34189. [CrossRef]
10. Franciszkiewicz, K.; Boissonnas, A.; Boutet, M.; Combadière, C.; Mami-Chouaib, F. Role of chemokines and chemokine receptors
in shaping the effector phase of the antitumor immune response. Cancer Res. 2012, 72, 6325–6332. [CrossRef]
11. Conroy, M.J.; Lysaght, J. CX3CL1 Signaling in the Tumor Microenvironment. Adv. Exp. Med. Biol. 2020, 1231, 1–12. [CrossRef]
12. Wendel, M.; Galani, I.E.; Suri-Payer, E.; Cerwenka, A. Natural Killer Cell Accumulation in Tumors Is Dependent on IFN-γ and
CXCR3 Ligands. Cancer Res. 2008, 68, 8437–8445. [CrossRef]
13. Liang, Y.; Yi, L.; Liu, P.; Jiang, L.; Wang, H.; Hu, A.; Sun, C.; Dong, J. CX3CL1 involves in breast cancer metastasizing to the spine
via the Src/FAK signaling pathway. J. Cancer 2018, 9, 3603–3612. [CrossRef]
14. Jamieson-Gladney, W.L.; Zhang, Y.; Fong, A.M.; Meucci, O.; Fatatis, A. The chemokine receptor CX3CR1 is directly involved in
the arrest of breast cancer cells to the skeleton. Breast Cancer Res. 2011, 13, R91. [CrossRef]
15. Andre, F.; Cabioglu, N.; Assi, H.; Sabourin, J.C.; Delaloge, S.; Sahin, A.; Broglio, K.; Spano, J.P.; Combadiere, C.; Bucana, C.; et al.
Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast
cancer. Ann. Oncol. 2006, 17, 945–951. [CrossRef]
16. White, G.E.; Tan, T.C.; John, A.E.; Whatling, C.; McPheat, W.L.; Greaves, D.R. Fractalkine has anti-apoptotic and proliferative
effects on human vascular smooth muscle cells via epidermal growth factor receptor signalling. Cardiovasc. Res. 2009, 85, 825–835.
[CrossRef]
17. Tardáguila, M.; Mira, E.; García-Cabezas, M.A.; Feijoo, A.M.; Quintela-Fandino, M.; Azcoitia, I.; Lira, S.A.; Mañes, S. CX3CL1
Promotes Breast Cancer via Transactivation of the EGF Pathway. Cancer Res. 2013, 73, 4461–4473. [CrossRef]
18. Bazan, J.F.; Bacon, K.B.; Hardiman, G.; Wang, W.; Soo, K.; Rossi, D.; Greaves, D.R.; Zlotnik, A.; Schall, T.J. A new class of
membrane-bound chemokine with a CX3C motif. Nature 1997, 385, 640–644. [CrossRef]
19. Bronger, H.; Magdolen, V.; Goettig, P.; Dreyer, T. Proteolytic chemokine cleavage as a regulator of lymphocytic infiltration in solid
tumors. Cancer Metastasis Rev. 2019, 38, 417–430. [CrossRef]
20. Mullooly, M.; McGowan, P.M.; Kennedy, S.A.; Madden, S.F.; Crown, J.; O’Donovan, N.; Duffy, M.J. ADAM10: A new player in
breast cancer progression? Br. J. Cancer 2015, 113, 945–951. [CrossRef]
21. Hundhausen, C.; Misztela, D.; Berkhout, T.A.; Broadway, N.; Saftig, P.; Reiss, K.; Hartmann, D.; Fahrenholz, F.; Postina, R.;
Matthews, V.; et al. The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine)
and regulates CX3CL1-mediated cell-cell adhesion. Blood 2003, 102, 1186–1195. [CrossRef] [PubMed]
22. Park, M.H.; Lee, J.S.; Yoon, J.H. High expression of CX3CL1 by tumor cells correlates with a good prognosis and increased
tumor-infiltrating CD8+ T cells, natural killer cells, and dendritic cells in breast carcinoma. J. Surg. Oncol. 2012, 106, 386–392.
[CrossRef] [PubMed]
23. Tsang, J.Y.S.; Ni, Y.-B.; Chan, S.-K.; Shao, M.-M.; Kwok, Y.-K.; Chan, K.-W.; Tan, P.H.; Tse, G.M. CX3CL1 expression is associated
with poor outcome in breast cancer patients. Breast Cancer Res. Treat. 2013, 140, 495–504. [CrossRef] [PubMed]
24. Wege, A.K.; Ernst, W.; Eckl, J.; Frankenberger, B.; Vollmann-Zwerenz, A.; Männel, D.N.; Ortmann, O.; Kroemer, A.; Brockhoff, G.
Humanized tumor mice-A new model to study and manipulate the immune response in advanced cancer therapy. Int. J. Cancer
2011, 129, 2194–2206. [CrossRef]
25. Wege, A.K.; Schmidt, M.; Ueberham, E.; Ponnath, M.; Ortmann, O.; Brockhoff, G.; Lehmann, J. Co-transplantation of human
hematopoietic stem cells and human breast cancer cells in NSG mice: A novel approach to generate tumor cell specific human
antibodies. mAbs 2014, 6, 968–977. [CrossRef]
26. Wege, A.K.; Weber, F.; Kroemer, A.; Ortmann, O.; Nimmerjahn, F.; Brockhoff, G. IL-15 enhances the anti-tumor activity of
trastuzumab against breast cancer cells but causes fatal side effects in humanized tumor mice (HTM). Oncotarget 2016, 8,
2731–2744. [CrossRef]
27. Rom-Jurek, E.-M.; Kirchhammer, N.; Ugocsai, P.; Ortmann, O.; Wege, A.K.; Brockhoff, G. Regulation of Programmed Death
Ligand 1 (PD-L1) Expression in Breast Cancer Cell Lines In Vitro and in Immunodeficient and Humanized Tumor Mice. Int. J.
Mol. Sci. 2018, 19, 563. [CrossRef]
28. Dreyer, T.F.; Kuhn, S.; Stange, C.; Heithorst, N.; Schilling, D.; Jelsma, J.; Sievert, W.; Seitz, S.; Stangl, S.R.; Hapfelmeier, A.; et al. The
chemokine CX3CL1 improves trastuzumab efficacy in HER2-low-expressing cancer in vitro and in vivo. Cancer Immunol. Res. 2021.
[CrossRef]
29. Magnifico, A.; Albano, L.; Campaner, S.; Campiglio, M.; Pilotti, S.; Ménard, S.; Tagliabue, E. Protein Kinase Cα Determines HER2
Fate in Breast Carcinoma Cells with HER2 Protein Overexpression without Gene Amplification. Cancer Res. 2007, 67, 5308–5317.
[CrossRef]
30. Yan, X.; Lin, J.; Talabattula, V.A.N.; Mußmann, C.; Yang, F.; Wree, A.; Rolfs, A.; Luo, J. ADAM10 Negatively Regulates Neuronal
Differentiation during Spinal Cord Development. PLoS ONE 2014, 9, e84617. [CrossRef]
31. Wege, A.K.; Kirchhammer, N.; Kazandjian, L.V.; Prassl, S.; Brandt, M.; Piendl, G.; Ortmann, O.; Fischer, S.; Brockhoff, G. A novel
rabbit derived anti-HER2 antibody with pronounced therapeutic effectiveness on HER2-positive breast cancer cells in vitro and
in humanized tumor mice (HTM). J. Transl. Med. 2020, 18, 1–16. [CrossRef]
32. Ohta, M.; Tanaka, F.; Yamaguchi, H.; Sadanaga, N.; Inoue, H.; Mori, M. The high expression of Fractalkine results in a better
prognosis for colorectal cancer patients. Int. J. Oncol. 2005, 26, 41–47. [CrossRef]
Cancers 2021, 13, 2459 19 of 19
33. Hyakudomi, M.; Matsubara, T.; Hyakudomi, R.; Yamamoto, T.; Kinugasa, S.; Yamanoi, A.; Maruyama, R.; Tanaka, T. Increased
Expression of Fractalkine is Correlated with a Better Prognosis and an Increased Number of Both CD8+ T Cells and Natural
Killer Cells in Gastric Adenocarcinoma. Ann. Surg. Oncol. 2008, 15, 1775–1782. [CrossRef]
34. Zhang, X.; Wei, H.; Chen, Q.; Tian, Z. Activation of human natural killer cells by recombinant membrane-expressed frac-talkine
on the surface of tumor cells. Oncol. Rep. 2007, 17, 1371–1375.
35. Zhang, J.; Yang, W.; Luo, B.; Hu, B.; Maheshwari, A.; Fallon, M.B. The role of CX3CL1/CX3CR1 in pulmonary angiogenesis and
intravascular monocyte accumulation in rat experimental hepatopulmonary syndrome. J. Hepatol. 2012, 57, 752–758. [CrossRef]
36. Ryu, J.; Lee, C.-W.; Hong, K.-H.; Shin, J.-A.; Lim, S.-H.; Park, C.-S.; Shim, J.; Nam, K.B.; Choi, K.-J.; Kim, Y.-H.; et al. Activation of
fractalkine/CX3CR1 by vascular endothelial cells induces angiogenesis through VEGF-A/KDR and reverses hindlimb ischaemia.
Cardiovasc. Res. 2007, 78, 333–340. [CrossRef]
37. Marchica, V.; Toscani, D.; Corcione, A.; Bolzoni, M.; Storti, P.; Vescovini, R.; Ferretti, E.; Accardalla Palmai, B.D.; Vicario, E.;
Accardi, F.; et al. Bone Marrow CX3CL1/Fractalkine is a New Player of the Pro-Angiogenic Microenvironment in Multiple
Myeloma Patients. Cancers 2019, 11, 321. [CrossRef]
38. Park, Y.; Lee, J.; Kwak, J.-Y.; Noh, K.; Yim, E.; Kim, H.-K.; Kim, Y.J.; Broxmeyer, H.E.; Kim, J.-A. Fractalkine induces angiogenic
potential in CX3CR1-expressing monocytes. J. Leukoc. Biol. 2017, 103, 53–66. [CrossRef]
39. Van Der Leun, A.M.; Thommen, D.S.; Schumacher, T.N. CD8+ T cell states in human cancer: Insights from single-cell analysis.
Nat. Rev. Cancer 2020, 20, 218–232. [CrossRef]
40. Gros, A.; Robbins, P.F.; Yao, X.; Li, Y.F.; Turcotte, S.; Tran, E.; Wunderlich, J.R.; Mixon, A.; Farid, S.; Dudley, M.E.; et al. PD-1
identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. J. Clin. Investig. 2014, 124, 2246–2259.
[CrossRef]
41. Saftig, P.; Reiss, K. The “A Disintegrin And Metalloproteases” ADAM10 and ADAM17: Novel drug targets with therapeutic
potential? Eur. J. Cell Biol. 2011, 90, 527–535. [CrossRef]
42. Moss, M.L.; Minond, D. Recent Advances in ADAM17 Research: A Promising Target for Cancer and Inflammation. Mediat.
Inflamm. 2017, 2017, 1–21. [CrossRef]
43. Smith, T.M.J.; Tharakan, A.; Martin, R.K. Targeting ADAM10 in Cancer and Autoimmunity. Front. Immunol. 2020, 11, 499.
[CrossRef]
44. McGowan, P.M.; Ryan, B.M.; Hill, A.D.; McDermott, E.; O’Higgins, N.; Duffy, M.J. ADAM-17 Expression in Breast Cancer
Correlates with Variables of Tumor Progression. Clin. Cancer Res. 2007, 13, 2335–2343. [CrossRef]
45. Duffy, M.J.; McKiernan, E.; O’Donovan, N.; McGowan, P.M. Role of ADAMs in Cancer Formation and Progression. Clin. Cancer
Res. 2009, 15, 1140–1144. [CrossRef]
46. McGowan, P.M.; McKiernan, E.; Bolster, F.; Ryan, B.M.; Hill, A.D.K.; McDermott, E.W.; Evoy, D.; O’Higgins, N.; Crown, J.; Duffy,
M.J. ADAM-17 predicts adverse outcome in patients with breast cancer. Ann. Oncol. 2008, 19, 1075–1081. [CrossRef]
47. Mezil, L.; Berruyer-Pouyet, C.; Cabaud, O.; Josselin, E.; Combes, S.; Brunel, J.-M.; Viens, P.; Collette, Y.; Birnbaum, D.; Lopez,
M. Tumor Selective Cytotoxic Action of a Thiomorpholin Hydroxamate Inhibitor (TMI-1) in Breast Cancer. PLoS ONE 2012, 7,
e43409. [CrossRef]
48. Venkatesh, H.S.; Tam, L.T.; Woo, P.J.; Lennon, J.; Nagaraja, S.; Gillespie, S.M.; Ni, J.; Duveau, D.Y.; Morris, P.J.; Zhao, J.J.; et al.
Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma. Nat. Cell Biol. 2017, 549, 533–537. [CrossRef]
49. Perrier, A.; Gligorov, J.; Lefevre, G.; Boissan, M. The extracellular domain of Her2 in serum as a biomarker of breast cancer. Lab.
Investig. 2018, 98, 696–707. [CrossRef]
50. Friedman, S.; Levy, R.; Garrett, W.; Doval, D.; Bondarde, S.; Sahoo, T.; Lokanatha, D.; Julka, P.; Shenoy, K.; Nagarkar, R.; et al.
Clinical Benefit of INCB7839, a Potent and Selective Inhibitor of ADAM10 and ADAM17, in Combination with Trastuzumab
in Metastatic HER2 Positive Breast Cancer Patients. In Poster Sessio Abstracts, Proceedings of the Abstracts: Thirty-Second Annual
CTRC-AACR San Antonio Breast Cancer Symposium San Antonio, TX, USA, 10–13 December 2009; American Association for Cancer
Research: Philadelphia, PA, USA, 2009; Volume 69, p. 5056.
